- Cancer research
- Career spotlights
- Current events
- Customer stories
- Gene editing
- Research news
- Single-cell analysis
- Stem cell research
Tips and troubleshooting
- Best practices for RNA-seq: Optimizing sample prep
- Your quest for a better diagnostic assay development partner ends here
- Designing primers for site-directed mutagenesis
- Qualities to look for in your ideal OEM partner
- Understanding viral titration—behind the science
- 4 factors to consider for immune repertoire profiling
- 5 FACS tips for scRNA-seq
- Choosing a his-tagged purification resin
- 5 tips to make your single-cell RNA-seq experiments a success
- Using UMIs in NGS experiments
- Web and mobile apps
- One-step vs. two-step RT-qPCR
- Avoid DNA contamination in PCR
- When your his-tagged constructs don't bind
- Women in STEM
- That's Good Support!
- About our blog
Understanding viral titration—behind the science
No matter your end goal—be it protein expression, high-throughput screening, cell engineering, etc.—taking the time to titrate your virus will increase the likelihood of a successful transduction. Knowing the number of particles, or infectious units, in your viral prep is important because it largely determines the transduction efficiency (i.e., how many viruses get into a cell), and thus the number of integrated gene copies in the transduced target cell. It is, therefore, worth taking time to understand the different measurement methods and how they relate to one another. Here's a crash course on lentiviral titration to get your experiments started on the right foot.
Lentiviral production basics
There are two common measurement types: physical, which determine particle concentration by measuring corresponding nucleic acid or protein amounts, or functional, which count particles capable of productive transduction (IFU/ml). To understand what is being measured in these methods, let's consider a lentiviral production workflow (Figure 1) to see what is being produced in a typical prep.
Recombinant lentiviruses are produced by cloning a sequence of interest into a lentiviral backbone containing all the necessary cis-acting elements required for virus function (Figure 1, Panel B). The resulting transfer vector is then mixed with a plasmid-based packaging mix that provides all the viral proteins required for virus particle production within a packaging cell. The transfer and packaging vectors are then combined with a transfection reagent (lipid or polymer), and the mixture is used to transfect a producer cell line, typically 293T-based cells, that can efficiently express the transfected constructs.
|Long terminal repeat (LTR)||Mediates integration of retroviral DNA into the host chromosome.|
|Lentiviral packaging signal (Ψ)||Regulates the packaging of the viral genome into a capsid.|
|Rev response element (RRE)||Increases titers by promoting the nuclear export of unspliced viral genomic RNA.|
|Central polypurine tract/central termination (cPPT)||Creates a DNA "flap" that increases the nuclear importation of the viral genome during target-cell infection. The cPPT/CTS element improves vector integration and transduction efficiency.|
|Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE)||Prevents poly(A) site readthrough, promotes RNA processing and maturation, and increases nuclear export of RNA. In genomic transcripts, it enhances vector packaging and increases titer. In transduced target cells, the WPRE boosts transgene expression by facilitating mRNA transcript maturation.|
Figure 1. Example lentiviral production workflow. Panel A. Workflow for Takara Bio's fourth-generation lentiviral packaging system. Panel B. Cis-acting elements in Takara Bio lentiviral vectors. Elements are derived from HIV-1.
The result is the release of viral particles into the supernatant. This output (Figure 2) includes fully complete and infectious particles, noninfectious particles, and free capsid proteins (i.e., p24). Physical titration measurements—qRT-PCR, p24 ELISAs, and Lenti-X GoStix Plus—are relatively straightforward to perform, but count both functional and nonfunctional virus particles (directly and/or via analysis of viral components released into supernatant). In contrast, functional titration methods specifically quantify particles capable of transducing target cells (i.e., infectious units or IFU), but are lengthier and more laborious.
A key aspect of viral titration is that when viral production methods (Figure 3) are applied consistently, the ratios between analytes measured using physical or functional methods remain constant. What does this mean for you? In a nutshell, to quantitatively compare one prep to another using a physical titration method, all the production and postproduction processing steps must be performed the same way, and with the same reagents.
|Packaging system||Ratios of IFUs to lentiviral particles can vary between systems|
|Purification/filtration||Lowers the amount of soluble p24 in the supernatant|
|Concentration/precipitation||Increases ratios of full and empty particles to soluble p24|
|Harvesting timepoint||Ratio of p24 to IFUs generally increases over time|
Figure 3. Influence of production methods on relationships between physical and functional measurements.
Let's get physical
The great news is that while physical titration methods may not quantify functional particles directly, they provide rapid, reliable alternatives to functional titration methods once a relationship between the two measurements has been established. For example, let's examine how a Lenti-X GoStix Plus assay measurement can be converted to an IFU/ml value with a little bit of math and a reference titer. Don't run away; we promise it will be simple!
When you scan a GoStix cassette with the accompanying app, the app's software uses densitometry to quantitate and compare band intensities on the cassette and then consults a lot-specific standard curve loaded onto your device to determine the corresponding quantity of p24 in the sample (ng/ml p24). To convert this GoStix measurement into a functional titer, a reference virus prepared using the exact conditions as your typical prep must first be measured using both a GoStix cassette and a functional titration method to determine the number of positively transduced cells per ml of supernatant from the reference virus prep (IFU/ml). Once both numbers are obtained, the ratio of IFU/ml to ng/ml p24 can be calculated. This value can then be used to convert any future measurements of ng/ml p24 to corresponding IFU/ml if the conditions and components are kept the same.
|Reference vector functional titer =||2.2 x 108 IFU/ml|
|÷ Reference vector physical titer =||525 ng/ml p24|
|Reference vector ratio =||4.2 x 105 IFU/ng p24|
|Physical titer for unknown vector (measured) =||790 ng/ml p24|
|X Reference vector ratio (from above) =||4.2 x 105 IFU/ng p24|
|Functional titer for vector to be (calculated) =||3.3 x 108 IFU/ml|
From titration to assays in a snap
Lentiviral titration is a critical aspect of viral transduction workflows because it ensures that preps are applied in sufficient quantities to obtain desired transduction efficiencies. However, traditional physical (e.g., qRT-PCR and ELISAs) and functional titration assays can be long and cumbersome, lengthening the time until you can get to your downstream assays. Since ratios of titration values obtained using physical and functional methods should be constant for a given lentiviral production workflow, this ratio can be used to convert measurements from a quick-and-easy physical titration method to a useful functional value. Now, you are a titration expert!
Your research time is valuable, so we've developed the 10-min Lenti-X GoStix Plus assay to provide a more rapid alternative to other physical titration methods such as qPCR and ELISA. Just apply your sample, wait ten minutes, and take a photo using the app. It's that easy!
Back to Blog Front
Lentiviral tools and tips
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.